Skip to search formSkip to main contentSkip to account menu

imatinib 400 MG Oral Tablet [Gleevec]

Known as: Gleevec 400 MG Oral Tablet, IMATINIB MESYLATE 400 mg ORAL TABLET [Gleevec] 
National Institutes of Health

Related topics

Related topics

14 relations
CrospovidoneGleevecImatinib mesylateMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.
2009
2009
RUNX1T1 is overexpressed in imatinib mesylate-resistant cells.
The Philadelphia (Ph) chromosome, which occurs as a result of a translocation between chromosomes 9 and 22, generates a BCR-ABL… 
2009
2009
Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with…
Abstract 1724 Poster Board I-750 The success of imatinib (IM, formerly STI571, Gleevec ® ) in the treatment of chronic myeloid… 
2008
2008
Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters
Tyrosine kinase inhibitors (TKIs) that preferentially inhibit the oncogenic Bcr-Abl fusion protein have radically changed the… 
2008
2008
Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations
Imatinib mesylate (Gleevec® Novartis) is an important, new, molecularly targeted, anti-cancer agent with clinical efficacy in… 
2008
2008
Standardizing the Decision Process to Personalize a Therapy with a Theranostic : The Options for Test Index ( OFT i )
While the top pharmaceutical companies have all made investments at an R&D stage in biomarkers and genetics to aid drug selection… 
2007
2007
A Radioprotective Effect of Imatinib (Gleevec®) in Human Squamous Carcinoma Cells
Purpose:To study the radiation response-modifying effect of imatinib (Gleevec®) in a squamous cell carcinoma line, PECA.Patients… 
2007
2007
A remedy for biomarker addiction: back to rational anticancer drug development
The authors of this Viewpoint argue there are no facile solutions to replace the painstaking, empirical effort required to… 
2006
2006
Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference
We compared antisense phosphorothioate oligonucleotides (PS-ODN) that target BCL-2 such as Genasense® (G3139-PS), with other PS… 
Review
2005
Review
2005
Oncogenes as Novel Targets for Cancer Therapy (Part I)
In the past 10 years, progress made in cancer biology, genetics, and biotechnology has led to a major transition in cancer drug… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)